CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a new therapy for nonalcoholic fatty liver disease (NAFLD) by targeting excess microRNA-132. The goal is to create a pharmaceutical treatment that can reverse NAFLD and its progression to more severe liver conditions, addressing a significant health challenge with currently no effecti…
Development of anti-microRNA therapeutic for nonalcoholic fatty liver disease Nonalcoholic fatty liver disease (NAFLD) initiates with excessive accumulation of liver triglycerides and progresses to nonalcoholic steatohepatitis (NASH), cirrhosis and liver cancer while also modifying brain metabolism.
However, NAFLD pathogenesis, the corresponding impact on the brain and the links between them, are poorly understood.
In addition NAFLD is largely untreatable.
We have discovered that excess microRNA…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
